Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompanyBAL PHARMA LTD. 2CIN NO.L85110KA1987PLC008368 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 44.81 4Highest Credit Rating during the previous FY BBB- 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)ACUITE RATINGS & RESEARCH LIMITED 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: Abdul Basith Designation: Company Secretary EmailId: secretarial@balpharma.com Name of the Chief Financial Officer: Bharath Bhushan Designation: CFO EmailId: secretarial@balpharma.com Date: 02/04/2024 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.